Virax Biolabs Group Limited (VRAX)
(Delayed Data from NSDQ)
$0.78 USD
-0.01 (-0.78%)
Updated Aug 8, 2025 03:40 PM ET
After-Market: $0.79 +0.01 (0.78%) 7:58 PM ET
3-Hold of 5 3
B Value F Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
VRAX 0.78 -0.01(-0.78%)
Will VRAX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for VRAX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRAX
Zacks Investment Ideas feature highlights: Virax Biolabs Group, GeoVax Labs, Applied DNA Sciences and Emergent BioSolutions
WHO Declares Monkeypox Public Emergency: 5 Mpox Stocks to Watch
VRAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for VRAX
Virax Biolabs Appoints Iain Miller, PhD as Independent Director to Accelerate Commercial ...
Virax Biolabs (VRAX) Faces Nasdaq Compliance Challenge | VRAX Stock News
Virax Biolabs receives noncompliance notice from Nasdaq
Virax Biolabs Announces Receipt of NASDAQ Notification Letter Regarding Minimum Bid Price ...
Virax Biolabs receives Nasdaq letter over non-compliance with minimum bid price rule